Iodinated Contrast Agents Reduce the Efficacy of Intravenous Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients: a Multicenter Cohort Study
- 1 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Stroke Research
- Vol. 12 (4), 530-539
- https://doi.org/10.1007/s12975-020-00846-5
Abstract
This study aimed to investigate whether the application of iodinated contrast agents before intravenous (IV) recombinant tissue plasminogen activator (rt-PA) reduces the efficacy in acute ischemic stroke (AIS) patients. To determine whether the application of iodinated contrast agents before intravenous rt-PA reduces the efficacy in AIS patients. We analyzed our prospectively collected data of consecutive AIS patients receiving IV rt-PA treatment in the MISSION CHINA study. Clinical outcome at 3 months was assessed with modified Rankin Scale (mRS) score and dichotomized into good outcome (0-2) and poor outcome (3-6). Symptomatic intracerebral hemorrhage (sICH) was defined as cerebral hemorrhagic transformation in combination with clinical deterioration of National Institutes of Health Stroke Scale (NIHSS) score >= 4 points at 24-h. We performed logistic regression analysis and propensity score matching analysis to investigate the impact of iodinated contrast agents before IV rt-PA on poor outcome and sICH, respectively. A total of 3593 patients were finally included, and iodinated contrast agents were used before IV rt-PA among 859 (23.9%) patients. Patients in the iodinated contrast group were more likely to result in poor outcome (39.9% vs 33.4%,P = 0.001) and sICH (3.4% vs 1.5%,P < 0.001), compared with non-contrast group. Binary logistic regression analysis revealed that the application of iodinated contrast agents was independently associated with poor outcome (OR 1.342; 95% CI 1.103-1.631;P = 0.003) and sICH (OR 1.929; 95% CI 1.153-3.230;P = 0.012), respectively. After propensity score matching, the application of iodinated contrast agents was still independently associated with poor outcome (OR 1.246; 95% CI 1.016-1.531;P = 0.034) and sICH (OR 1.965; 95% CI 1.118-3.456;P = 0.019). Applying iodinated contrast agents before IV rt-PA may reduce the thrombolytic efficacy in AIS patients. Further benefit-risk analysis might be needed when iodinated contrast-used imaging is considered before intravenous thrombolysis.Funding Information
- National Key Research and Development Program of China (2016YFC1300504)
- National Natural Science Foundation of China (81622017, 81601017)
- Science Technology Department of Zhejiang Province (2018C04011)
This publication has 39 references indexed in Scilit:
- Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of StrokeThe New England Journal of Medicine, 2019
- 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationStroke, 2018
- Acute Ischemic Stroke Therapy OverviewCirculation Research, 2017
- Iodinated Contrast Does Not Alter Clotting Dynamics in Acute Ischemic Stroke as Measured by ThromboelastographyStroke, 2014
- Does the Application of X-Ray Contrast Agents Impair the Clinical Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients?Stroke, 2012
- Microcatheter contrast injections during intra-arterial thrombolysis increase intracranial hemorrhage riskJournal of NeuroInterventional Surgery, 2010
- Do Iodinated Contrast Agents Impair Fibrinolysis in Acute Stroke? A Systematic ReviewAmerican Journal of Neuroradiology, 2009
- In vivo effects of contrast media on coronary thrombolysisJournal of the American College of Cardiology, 1998
- Are iodinated contrast agents detrimental in acute cerebral ischemia? An experimental study in rats.Radiology, 1998
- Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agentsJournal of the American College of Cardiology, 1995